{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:39:12Z","timestamp":1790271552430,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.vaccine.2012.03.028","type":"journal-article","created":{"date-parts":[[2012,3,30]],"date-time":"2012-03-30T05:18:18Z","timestamp":1333084698000},"page":"3683-3690","source":"Crossref","is-referenced-by-count":31,"title":["Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis"],"prefix":"10.1016","volume":"30","author":[{"given":"Bas","family":"van de Waterbeemd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Streefland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lonneke","family":"van Keulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van den IJssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel H.","family":"Eppink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A.","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"May (22)","key":"10.1016\/j.vaccine.2012.03.028_bib0005","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1016\/j.vaccine.2006.03.034","article-title":"A review of vaccine research and development: meningococcal disease","volume":"24","author":"Girard","year":"2006","journal-title":"Vaccine"},{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2012.03.028_bib0010","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"issue":"April (9316)","key":"10.1016\/j.vaccine.2012.03.028_bib0015","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(02)08416-7","article-title":"Development of vaccines against meningococcal disease","volume":"359","author":"Jodar","year":"2002","journal-title":"Lancet"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.03.028_bib0020","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1586\/erv.09.30","article-title":"Challenges and progress in the development of a serogroup B meningococcal vaccine","volume":"8","author":"Lewis","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2958.2009.06731.x","article-title":"Biogenesis of bacterial membrane vesicles","author":"Deatherage","year":"2009","journal-title":"Mol Microbiol"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2012.03.028_bib0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0264-410X(89)90194-1","article-title":"Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay","volume":"7","author":"Saukkonen","year":"1989","journal-title":"Vaccine"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2012.03.028_bib0035","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1. 7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"February (9)","key":"10.1016\/j.vaccine.2012.03.028_bib0040","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.vaccine.2005.09.043","article-title":"Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control","volume":"24","author":"Thornton","year":"2006","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/517385","article-title":"New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4","volume":"177","author":"Martin","year":"1998","journal-title":"J Infect Dis"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0050","first-page":"195","article-title":"Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"December (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0055","first-page":"67","article-title":"Production, characterization and control of MenB-vaccine Folkehelsa: an outer membrane vesicle vaccine against group B meningococcal disease","volume":"14","author":"Fredriksen","year":"1991","journal-title":"NIPH Ann"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2012.03.028_bib0060","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1128\/IAI.69.10.5981-5990.2001","article-title":"Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity","volume":"69","author":"van der Ley","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.08.048","article-title":"A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression","author":"Keiser","year":"2010","journal-title":"Vaccine"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2012.03.028_bib0070","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1128\/IAI.73.7.4070-4080.2005","article-title":"Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination","volume":"73","author":"Fisseha","year":"2005","journal-title":"Infect Immun"},{"issue":"July (30)","key":"10.1016\/j.vaccine.2012.03.028_bib0075","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1016\/j.vaccine.2010.04.082","article-title":"Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process","volume":"28","author":"van de Waterbeemd","year":"2010","journal-title":"Vaccine"},{"issue":"July (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1086\/589308","article-title":"Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin","volume":"198","author":"Koeberling","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0085","article-title":"Meningococcal OMV vaccines from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2","author":"Koeberling","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0090","article-title":"Lipoproteins of bacterial pathogens","author":"Kovacs-Simon","year":"2010","journal-title":"Infect Immun"},{"issue":"November (46)","key":"10.1016\/j.vaccine.2012.03.028_bib0095","doi-asserted-by":"crossref","first-page":"38383","DOI":"10.1074\/jbc.M508063200","article-title":"Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B","volume":"280","author":"Post","year":"2005","journal-title":"J Biol Chem"},{"issue":"December (3)","key":"10.1016\/j.vaccine.2012.03.028_bib0100","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0005-2736(76)90058-4","article-title":"Release of outer membrane fragments from normally growing Escherichia coli","volume":"455","author":"Hoekstra","year":"1976","journal-title":"Biochim Biophys Acta"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2012.03.028_bib0105","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1084\/jem.138.5.1156","article-title":"Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis","volume":"138","author":"Devoe","year":"1973","journal-title":"J Exp Med"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2012.03.028_bib0110","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2958.2003.03903.x","article-title":"Structure of the OmpA-like domain of RmpM from Neisseria meningitidis","volume":"51","author":"Grizot","year":"2004","journal-title":"Mol Microbiol"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2012.03.028_bib0115","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1128\/IAI.57.7.2066-2071.1989","article-title":"Sequence of the structural gene (rmpM) for the class 4 outer membrane protein of Neisseria meningitidis, homology of the protein to gonococcal protein III and Escherichia coli OmpA, and construction of meningococcal strains that lack class 4 protein","volume":"57","author":"Klugman","year":"1989","journal-title":"Infect Immun"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2012.03.028_bib0120","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/pmic.200500164","article-title":"Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles","volume":"6","author":"Ferrari","year":"2006","journal-title":"Proteomics"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.03.028_bib0125","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1745-7270.2007.00350.x","article-title":"EDTA-induced membrane fluidization and destabilization: biophysical studies on artificial lipid membranes","volume":"39","author":"Prachayasittikul","year":"2007","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0130","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1128\/AAC.6.2.200","article-title":"Effect of chelating agents on the susceptibility of some strains of gram-negative bacteria to some antibacterial agents","volume":"6","author":"Haque","year":"1974","journal-title":"Antimicrobial Agents Chemother"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.03.028_bib0135","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1128\/AAC.5.5.447","article-title":"Effect of ethylenediaminetetraacetic acid and related chelating agents on whole cells of gram-negative bacteria","volume":"5","author":"Haque","year":"1974","journal-title":"Antimicrobial Agents Chemother"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2012.03.028_bib0140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/IAI.6.5.835-851.1972","article-title":"Isolation and characterization of a native cell wall complex from Neisseria meningitidis","volume":"6","author":"Zollinger","year":"1972","journal-title":"Infect Immun"},{"issue":"August (1\u20132)","key":"10.1016\/j.vaccine.2012.03.028_bib0145","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0264-410X(99)00216-9","article-title":"Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers","volume":"18","author":"Drabick","year":"1999","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0150","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/IAI.70.2.702-707.2002","article-title":"Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine","volume":"70","author":"Katial","year":"2002","journal-title":"Infect Immun"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.03.028_bib0155","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1128\/IAI.72.5.2528-2537.2004","article-title":"Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis","volume":"72","author":"Guthrie","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.08.048","article-title":"A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA","author":"Keiser","year":"2010","journal-title":"Vaccine"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2012.03.028_bib0165","article-title":"Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants","volume":"7","author":"van der Ley","year":"2011","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0170","doi-asserted-by":"crossref","unstructured":"Perez-Pardo MA, Ali S, Balasundaram B, Mannall GJ, Baganz F, Bracewell DG. Assessment of the manufacturability of Escherichia coli high cell density fermentations. Biotechnol Progr 2011; May 2.","DOI":"10.1002\/btpr.644"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0175","series-title":"Meningococcal vaccines, methods and protocols","author":"Frasch","year":"2001"},{"issue":"August (159)","key":"10.1016\/j.vaccine.2012.03.028_bib0180","first-page":"44928","article-title":"International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological\/biological products. Notice. Food and Drug Administration, HHS","volume":"64","author":"ICH","year":"1999","journal-title":"Fed Regist"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.03.028_bib0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nbt0109-26","article-title":"Quality by design for biopharmaceuticals","volume":"27","author":"Rathore","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"June (109)","key":"10.1016\/j.vaccine.2012.03.028_bib0190","first-page":"27325","article-title":"International Conference on Harmonisation; guidance on Q8(R1) pharmaceutical development; addition of annex; availability. Notice","volume":"74","author":"ICH","year":"2009","journal-title":"Fed Regist"},{"issue":"September (9)","key":"10.1016\/j.vaccine.2012.03.028_bib0195","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tibtech.2009.06.006","article-title":"Roadmap for implementation of quality by design (QbD) for biotechnology products","volume":"27","author":"Rathore","year":"2009","journal-title":"Trends Biotechnol"},{"issue":"December (5)","key":"10.1016\/j.vaccine.2012.03.028_bib0200","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/bit.22016","article-title":"Modeling Neisseria meningitidis B metabolism at different specific growth rates","volume":"101","author":"Baart","year":"2008","journal-title":"Biotechnol Bioeng"},{"issue":"May (1\u20132)","key":"10.1016\/j.vaccine.2012.03.028_bib0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jim.2004.03.002","article-title":"Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis","volume":"288","author":"Gaines Das","year":"2004","journal-title":"J Immunol Methods"},{"issue":"March (17\u201318)","key":"10.1016\/j.vaccine.2012.03.028_bib0210","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"issue":"January (7\u20138)","key":"10.1016\/j.vaccine.2012.03.028_bib0215","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","article-title":"Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease","volume":"21","author":"Holst","year":"2003","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0220","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/jcm.9.2.186-188.1979","article-title":"Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978","volume":"9","author":"Holten","year":"1979","journal-title":"J Clin Microbiol"},{"issue":"March (4)","key":"10.1016\/j.vaccine.2012.03.028_bib0225","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0264-410X(95)98264-B","article-title":"Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine","volume":"13","author":"van der Ley","year":"1995","journal-title":"Vaccine"},{"issue":"August (34)","key":"10.1016\/j.vaccine.2012.03.028_bib0230","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1016\/j.vaccine.2007.06.008","article-title":"Scale-up for bulk production of vaccine against meningococcal disease","volume":"25","author":"Baart","year":"2007","journal-title":"Vaccine"},{"issue":"October (1)","key":"10.1016\/j.vaccine.2012.03.028_bib0235","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/0014-5793(75)80272-9","article-title":"Electrophoretic resolution of the major outer membrane protein of Escherichia coli K12 into four bands","volume":"58","author":"Lugtenberg","year":"1975","journal-title":"FEBS Lett"},{"issue":"March (13)","key":"10.1016\/j.vaccine.2012.03.028_bib0240","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.vaccine.2006.09.025","article-title":"Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs","volume":"25","author":"van den Dobbelsteen","year":"2007","journal-title":"Vaccine"},{"issue":"March (10)","key":"10.1016\/j.vaccine.2012.03.028_bib0245","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2005.10.003","article-title":"Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine","volume":"24","author":"Luijkx","year":"2006","journal-title":"Vaccine"},{"issue":"November (3\u20134)","key":"10.1016\/j.vaccine.2012.03.028_bib0250","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0264-410X(01)00371-1","article-title":"Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine","volume":"20","author":"de Kleijn","year":"2001","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.03.028_bib0255","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/IAI.67.1.113-119.1999","article-title":"Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice","volume":"67","author":"Saunders","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.05.006","article-title":"Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine","author":"Zollinger","year":"2010","journal-title":"Vaccine"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2012.03.028_bib0265","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/JB.151.3.1523-1531.1982","article-title":"Heat-induced blebbing and vesiculation of the outer membrane of Escherichia coli","volume":"151","author":"Katsui","year":"1982","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1134\/S1607672909030041","article-title":"Outer membrane vesicles of Lysobacter sp","volume":"426","author":"Vasilyeva","year":"2009","journal-title":"Doklady"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0275","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2958.2006.05522.x","article-title":"Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response","volume":"63","author":"McBroom","year":"2007","journal-title":"Mol Microbiol"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2012.03.028_bib0280","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1042\/bj0960567","article-title":"An extracellular glycolipid produced by Escherichia coli grown under lysine-limiting conditions","volume":"96","author":"Bishop","year":"1965","journal-title":"Biochem J"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2012.03.028_bib0285","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0022-2836(69)90374-X","article-title":"Synthesis and assembly of bacterial membrane components. A lipopolysaccharide\u2013phospholipid\u2013protein complex excreted by living bacteria","volume":"44","author":"Rothfield","year":"1969","journal-title":"J Mol Biol"},{"issue":"July (10)","key":"10.1016\/j.vaccine.2012.03.028_bib0290","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0264-410X(96)00020-5","article-title":"Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine","volume":"14","author":"Claassen","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.03.028_bib0295","unstructured":"Gorringe A, Vincent P, Halliwell D, Reddin K. Patent WO2006\/008504 A1: Stable compositions containing outer membrane vesicles, methods of manufacturing; 2006."},{"issue":"January (5\u20136)","key":"10.1016\/j.vaccine.2012.03.028_bib0300","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.vaccine.2003.08.027","article-title":"Stability of mono- and trivalent meningococcal outer membrane vesicle vaccines","volume":"22","author":"Arigita","year":"2004","journal-title":"Vaccine"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.03.028_bib0305","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/jgm.1383","article-title":"Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography","volume":"11","author":"Eglon","year":"2009","journal-title":"J Gene Med"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.03.028_bib0310","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bit.10878","article-title":"Combined in-fermenter extraction and cross-flow microfiltration for improved inclusion body processing","volume":"85","author":"Tin Lee","year":"2004","journal-title":"Biotechnol Bioeng"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1200391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1200391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T23:38:14Z","timestamp":1641685094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1200391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":62,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0264410X1200391X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.03.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}